Caroline Cohen

Summary

Affiliation: Sanofi-Synthelabo Recherche
Country: France

Publications

  1. ncbi request reprint SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
    C Cohen
    Sanofi Synthelabo, Bagneux, France
    Behav Pharmacol 13:451-63. 2002
  2. ncbi request reprint SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation
    C Cohen
    Central Nervous System Research Department, Sanofi Synthelabo Research, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    J Pharmacol Exp Ther 306:407-20. 2003
  3. ncbi request reprint Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
    Caroline Cohen
    Sanofi Synthelabo Recherche, Bagneux, France
    Neuropsychopharmacology 30:145-55. 2005
  4. ncbi request reprint Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models
    Caroline Louis
    Sanofi Aventis Research and Development, Psychopharmacology Department, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 89:36-45. 2008
  5. ncbi request reprint Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders
    Jeanne Stemmelin
    Sanofi Aventis, CNS Research, Bagneux, France
    Neuropsychopharmacology 33:574-87. 2008
  6. doi request reprint Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia
    Denis Boulay
    Sanofi Aventis, CNS Department, 31 Avenue Paul Vaillant Couturier, Bagneux, France
    Pharmacol Biochem Behav 91:47-58. 2008
  7. ncbi request reprint CB1 receptor antagonists for the treatment of nicotine addiction
    Caroline Cohen
    Sanofi Aventis, CNS Research Department, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 81:387-95. 2005
  8. doi request reprint Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress
    Jeanne Stemmelin
    Sanofi Aventis, CNS Research, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Behav Brain Res 206:310-2. 2010
  9. ncbi request reprint Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat
    Caroline Louis
    CNS Research Department, Sanofi Aventis, Bagneux, France
    Neuropsychopharmacology 31:2180-7. 2006
  10. ncbi request reprint SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms
    Guy Griebel
    CNS Research Department, Sanofi Synthelabo, 92220 Bagneux, France
    CNS Drug Rev 9:3-20. 2003

Collaborators

Detail Information

Publications11

  1. ncbi request reprint SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
    C Cohen
    Sanofi Synthelabo, Bagneux, France
    Behav Pharmacol 13:451-63. 2002
    ..Thus, SR141716 may be effective in reduction of alcohol consumption, as previously suggested, and as an aid for smoking cessation...
  2. ncbi request reprint SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation
    C Cohen
    Central Nervous System Research Department, Sanofi Synthelabo Research, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    J Pharmacol Exp Ther 306:407-20. 2003
    ....
  3. ncbi request reprint Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
    Caroline Cohen
    Sanofi Synthelabo Recherche, Bagneux, France
    Neuropsychopharmacology 30:145-55. 2005
    ..Rimonabant, which has been shown previously to reduce nicotine self-administration, may be effective not only as an aid for smoking cessation but also in the maintenance of abstinence...
  4. ncbi request reprint Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models
    Caroline Louis
    Sanofi Aventis Research and Development, Psychopharmacology Department, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 89:36-45. 2008
    ..Together, these results suggest further that the NK2 receptor may represent an attractive target for the treatment of both depressive and anxiety disorders...
  5. ncbi request reprint Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders
    Jeanne Stemmelin
    Sanofi Aventis, CNS Research, Bagneux, France
    Neuropsychopharmacology 33:574-87. 2008
    ..Taken as a whole, these findings indicate that the pharmacological stimulation of beta3 adrenoceptors may represent an innovative approach for the treatment of anxiety and depressive disorders...
  6. doi request reprint Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia
    Denis Boulay
    Sanofi Aventis, CNS Department, 31 Avenue Paul Vaillant Couturier, Bagneux, France
    Pharmacol Biochem Behav 91:47-58. 2008
    ..o.), respectively. These findings suggest that SSR103800 may have a therapeutic potential in the management of the core symptoms of schizophrenia and comorbid depression states...
  7. ncbi request reprint CB1 receptor antagonists for the treatment of nicotine addiction
    Caroline Cohen
    Sanofi Aventis, CNS Research Department, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 81:387-95. 2005
    ..Rimonabant may be considered as a potential alternative to the current substitutive treatments of nicotine addiction and may offer a new hope for the treatment of smokers who wish to quit...
  8. doi request reprint Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress
    Jeanne Stemmelin
    Sanofi Aventis, CNS Research, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Behav Brain Res 206:310-2. 2010
    ..This result suggests that the beta3-adrenoceptor plays a predominant role in mediating antidepressant-like actions of amibegron...
  9. ncbi request reprint Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat
    Caroline Louis
    CNS Research Department, Sanofi Aventis, Bagneux, France
    Neuropsychopharmacology 31:2180-7. 2006
    ....
  10. ncbi request reprint SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms
    Guy Griebel
    CNS Research Department, Sanofi Synthelabo, 92220 Bagneux, France
    CNS Drug Rev 9:3-20. 2003
    ..SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs...
  11. ncbi request reprint Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior
    Christine Duarte
    1INSERM U 288, Faculty of Medicine Pitié Salpêtrière, Paris, France
    Neuropsychopharmacology 29:911-20. 2004
    ..Overall, these results are consistent with the notion that endocannabinoid functions control brain reward processes and in particular the capacity of explicit stimuli to precipitate food-seeking behavior...